Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.

Document Type

Article

Abstract

BACKGROUND: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.

OBJECTIVES: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).

METHODS: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and "Off"/"On" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score.

RESULTS: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved "Off" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, "Off" time, QoL, and m-EDL.

CONCLUSIONS: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and "Off" time.

Medical Subject Headings

Humans; Quality of Life; Carbidopa; Levodopa; Drug Combinations; Parkinson Disease; Male; Antiparkinson Agents; Female; Middle Aged; Sleep; Aged; Treatment Outcome; Double-Blind Method; Activities of Daily Living

Publication Date

7-1-2024

Publication Title

Mov Disord Clin Pract

ISSN

2330-1619

Volume

11

Issue

7

First Page

861

Last Page

866

PubMed ID

38465885

Digital Object Identifier (DOI)

10.1002/mdc3.14018

This document is currently not available here.

Share

COinS